Showing results (511-520 of 1,188) with videos related to

Sort By:
Pageof 119
Pharmaceutical Statistics|February 12, 2026
Evaluating Safety Rules in Ongoing Dose-Escalation Trials Using BOIN: A Comparative Analysis of Criteria and Their Impact on Dose-Level Safety AssessmentsStefan Englert, Thomas J Prior, Anirban Mitra, et al.
Pharmaceutical Statistics|September 11, 2012
A structured approach to choosing estimands and estimators in longitudinal clinical trialsC H Mallinckrodt, Q Lin, I Lipkovich, et al.
Pharmaceutical Statistics|October 2, 2012
Sample size calculation for recurrent events data in one-arm studiesPaola Rebora, Stefania Galimberti
Pharmaceutical Statistics|July 28, 2020
Regional consistency and sample size considerations in a multiregional equivalence trialSi-Cheng Wu, Jin-Fang Xu, Xin-Ji Zhang, et al.
Pharmaceutical Statistics|August 11, 2020
Evaluating the time-dependent predictive accuracy for event-to-time outcome with a cure fractionZiwen Wang, Xiaoguang Wang
Pharmaceutical Statistics|May 16, 2014
A Bayesian dose-finding design for drug combination clinical trials based on the logistic modelMarie-Karelle Riviere, Ying Yuan, Frédéric Dubois, et al.
Pharmaceutical Statistics|June 20, 2014
Wilcoxon's signed-rank statistic: what null hypothesis and why it mattersHeng Li, Terri Johnson
Pharmaceutical Statistics|February 3, 2015
Phase I trial design for drug combinations with Bayesian model averagingIck Hoon Jin, Lin Huo, Guosheng Yin, et al.
Pharmaceutical Statistics|April 3, 2015
Likelihood-based inferences about the mean area under a longitudinal curve in the presence of observations subject to limits of detectionRameela Chandrasekhar, Yi Shi, Alan D Hutson, et al.
Pharmaceutical Statistics|July 11, 2020
Pharmacokinetic/pharmacodynamic data extrapolation models for improved pediatric efficacy and toxicity estimation, with application to secondary hyperparathyroidismCynthia Basu, Xiaoye Ma, May Mo, et al.
Pageof 119